**Core Concept:** Acid peptic disease refers to conditions like peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) where the acidity of the stomach or duodenum is increased leading to damage and inflammation of the mucosal lining. Drugs that reduce acid secretion are commonly used in the management of acid peptic diseases.

**Why the Correct Answer is Right:** The correct answer is D - Mefenamic acid (an NSAID) and Ranitidine (a H2-receptor antagonist) combination.

NSAIDs (Non-steroidal anti-inflammatory drugs) like mefenamic acid inhibit the production of prostaglandins in the gastrointestinal tract, causing increased risk of gastric mucosal damage and bleeding. H2-receptor antagonists like ranitidine decrease gastric acid secretion by blocking H2 receptors on gastric parietal cells, which reduces gastric acid production. Combining these two drugs would exacerbate the risk of gastric mucosal damage due to the additive effect of NSAID-induced inhibition of prostaglandin synthesis and ranitidine-induced reduction of gastric mucosal defense mechanisms.

**Why Each Wrong Option is Incorrect:**

A. Omeprazole (a proton pump inhibitor) and Ranitidine (a H2-receptor antagonist) combination is incorrect because omeprazole is a potent inhibitor of gastric acid secretion, unlike ranitidine which only moderately reduces gastric acid secretion. Combining them may lead to an excessive reduction of gastric acid secretion and potentially severe side effects.

B. Omeprazole (a proton pump inhibitor) and Amoxicillin (an antibiotic) combination is incorrect because amoxicillin is an antibiotic and does not address the acidity issue in acid peptic disease. A proton pump inhibitor like omeprazole is essential for reducing gastric acid secretion.

C. Alendronate (a bisphosphonate) and Omeprazole (a proton pump inhibitor) combination is incorrect because bisphosphonates are used for treating osteoporosis and do not address the acidity issue in acid peptic disease. Omeprazole reduces gastric acid secretion, which is more suitable for acid peptic disease management.

D. Mefenamic acid (an NSAID) and Omeprazole (a proton pump inhibitor) is incorrect because combining an NSAID like mefenamic acid with a proton pump inhibitor like omeprazole can lead to an increased risk of NSAID-induced gastric mucosal damage due to the additive effect of reduced gastric acid secretion and NSAID inhibition of prostaglandin synthesis.

**Clinical Pearl:**

In clinical practice, it is crucial to carefully consider drug combinations in terms of their individual pharmacological effects and potential adverse interactions. Always verify the therapeutic and potential harmful effects of drug combinations to ensure optimal patient care and minimize the risk of complications.